Gökçe ZEYTİN DEMİRAL, Ülkü TÜRK BÖRÜ, Cem BÖLÜK, Emel AHISHALI, Sanem COŞKUN DUMAN, Bahadır H DEMİRAL, Mustafa TAŞDEMİR

Irritable Bowel Syndrome In Multiple Sclerosis Patients and Its Relation To Attacks

Objective: Knowledge about bidirectional microbiome-gut-brain interactions has gradually increased in multiple sclerosis (MS) and many other diseases. The aim of this study is to determine the prevalence of irritable bowel syndrome (IBS) in MS patients, to compare with a control group and to identify the relationship between MS attacks and gastrointestinal (GI) symptoms. Methods: Patients with at least a two-year diagnosis of relapsing-remitting MS (RRMS) from our outpatient clinic were included in the study. The duration of disease, expanded disability status scale and time of MS attacks were recorded. ROME- IV criteria were used for diagnosis of IBS. Results were compared with the control group. IBS symptoms prior to, during and after an attack were recorded and their relationship to MS attacks was investigated. Results: 93 RRMS patients and 101 controls were included in this study. The prevalence rate of IBS was found to be 16.1% (n=15) in MS patients and 8.9% (n=9) in the control group. No significant difference can be found in IBS prevalence rate between MS patients and controls (p=0.127). MS attacks had no significant effect on constipation, diarrhea, abdominal pain and distention. Conclusion: This study showed that MS patients have a similar IBS prevalence to the control group. In addition, MS attacks have no significant effect on GI symptoms.

Multipl Skleroz Hastalarında İrritabl Barsak Sendromu ve Ataklarla Olan İlişkisi

Amaç: Multipl skleroz (MS) ve diğer hastalıklarda; mikrobiyom-barsak ve beynin iki yönlü etkileşimi konusundaki bilgi birikimi giderek artmaktadır. Bu çalışmanın amacı MS hastalarında irritabl barsak sendromu prevalansını belirlemek, kontrol grubu ile karşılaştırmak ve MS atakları ile gastrointestinal semptomlar arasındaki ilişkiyi belirlemektir. Yöntemler: Kliniğimizce en az 2 yıldır yineleyici MS (RRMS) teşhisi ile izlenen hastalar çalışmaya dâhil edildi. Hastalık süresi, özürlülük skalası (EDSS) ve MS atak zamanları kaydedildi. Irritabl barsak sendromu tanısında Roma-IV kriterleri kullanıldı. Sonuçlar kontrol grubu ile karşılaştırıldı. MS atakları öncesindeki, atak sırasındaki ve sonrasındaki gastrointestinal semptomlar kaydedilerek MS atakları ile ilişkisi araştırıldı. Bulgular: 93 RRMS hastası ve 101 kontrol çalışmaya dâhil edildi. MS hastalarında irritabl barsak sendromu prevalansı %16,1 (n=15) bulunurken, kontrol grubunda %8,9 (n=9) bulundu. İrritabl barsak sendromu sıklığı açısından MS hastaları ve sağlıklı kontroller arasında istatistiksel olarak anlamlı farklılık izlenmedi (p=0,127). MS ataklarının ishal, kabızlık, şişkinlik ve karın ağrısı üzerine anlamlı etkisi bulunamadı. Sonuç: Bu çalışma MS hastalarındaki irritabl barsak sendromu sıklığının sağlıklı kontroller ile benzer olduğunu göstermiştir. Ayrıca MS ataklarının gastrointestinal semptomlar üzerine anlamlı etkisi yoktur.

PDF

___

1.Marrie RA, Horwitz R, Cutter G, et al. Comorbiditydelays diagnosis and increases disability atdiagnosis in MS. Neurology 2009; 72: 117–24. doi:10.1212/01.wnl.0000333252.78173.5f.

2.Marrie RA, Rudick R, Horwitz R, et al. Vascularcomorbidity is associated with more rapid disabilityprogression in multiple sclerosis. Neurology 2010;74: 1041–7. doi: 10.1212/WNL.0b013e3181d6b125.

3.Köseoglu M, Gözübatik Çelik RG, Tütüncü M, ErbaşB.Quality of Life in Multiple Sclerosis: AreDepressive Findings as Effective as PhysicalDisability? Dicle Med J 2020; 47: 712-9. doi:10.5798/dicletip.800284.

4.Warren SA, Turpin KVL, Pohar SL, Jones CA,Warren KG. Comorbidity and health-related qualityof life in people with multiple sclerosis. Int J MS Care2009; 11: 6–16. doi: 10.7224/1537-2073-11.1.6.

5.Weinstock-Guttman B, Zivadinov R, Horakova D,et al. Lipid profiles are associated with lesionformation over 24 months in interferon-β treatedpatients following the first demyelinating event. JNeurol Neurosurg Psychiatry 2013; 84: 1186–91.doi: 10.1136/jnnp-2012-304740.

6. Fromont A, Binquet C, Rollot F, et al. Comorbiditiesat multiple sclerosis diagnosis. J Neurol 2013; 260:2629–37. doi: 10.1007/s00415-013-7041-9.

7.Kang JH, Chen YH, Lin HC. Comorbidities amongstpatients with multiple sclerosis: A population-basedcontrolled study. Eur J Neurol 2010; 17: 1215–9. doi:10.1111/j.1468-1331.2010.02971.x.

8.Guan XL, Wang H, Huang HS, Meng L. Prevalenceof dysphagia in multiple sclerosis: a systematicreview and meta-analysis. Neurol Sci 2015 May; 36:671-81. doi: 10.1007/s10072-015-2067-7.

9.Nusrat S, Gulick E, Levinthal D, Bielefeldt K.Anorectal dysfunction in multiple sclerosis: asystematic review. ISRN Neurol 2012; 2012:376023. doi: 10.5402/2012/376023.

10.Mayer EA, Savidge T, Shulman RJ. Brain-gutmicrobiome interactions and functional boweldisorders. Gastroenterology 2014; 146: 1500-12.doi: 10.1053/j.gastro.2014.02.037.

11.Marrie RA, Reider N, Stuve O, et al. The incidenceand prevalence of comorbid gastrointestinal,musculoskeletal, ocular, pulmonary, and renaldisorders in multiple sclerosis: a systematic review.Mult Scler 2015; 21: 332-41. doi:10.1177/1352458514564488.

12.Mearin F, Lacy BE, Chang L, et al. BowelDisorders. Gastroenterology 2016; 18: S0016-5085(16)00222-5. doi:10.1053/j.gastro.2016.02.031.

13. Özgürsoy Uran BN, Vardar R, Karadakovan A, BorS. The Turkish version of the Rome III criteria for IBSis valid and reliable. Turk J Gastroenterol 2014; 25:386-92. doi: 10.5152/tjg.2014.4774.

14.Polman CH, Reingold SC, Banwell B, et al.Diagnostic criteria for multiple sclerosis: 2010revisions to the McDonald criteria. Ann Neurol2011; 69. 2: 292-302. doi: 10.1002/ana.22366.

15.Kurtzke JF. Rating neurologic impairment inmultiple sclerosis an expanded disability statusscale (EDSS). Neurology 1983; 33: 1444-52. doi:10.1212/wnl.33.11.1444.

16.Karaman N, Türkay C, Yönem O. Irritable bowelsyndrome prevalence in city center of Sivas. Turk JGastroenterol 2003; 14: 128-31.

17.Celebi S, Acik Y, Deveci SE, et al. Epidemiologicalfeatures of irritable bowel syndrome in a Turkishurban society. J Gastroenterol Hepatol 2004; 19:738-43. doi: 10.1111/j.1440-1746.2004.03367.x.

18.Bytzer P, Talley NJ, Leemon M, et al. Prevalenceof gastrointestinal symptoms associated withdiabetes mellitus: a population-based survey of 15000 adults. Arch Intern Med 2001; 161: 1989-96.doi: 10.1001/archinte.161.16.1989.

19.Patten GS, Abeywardena MY. Effects ofantihypertensive agents on intestinal contractility inthe spontaneously hypertensive rat: angiotensinreceptor system downregulation by losartan. JPharmacol Exp Ther 2017; 360. 2: 260-6. doi:10.1124/jpet.116.237586.

20.Yakar B, Demir M. Evaluation of Adherence toAntihypertensive Drug Treatment Affecting Factorsin Patients with Chronic Renal Failure. Dicle Med J2019; 46: 685-96. doi: 10.5798/dicletip.661259.

21.Duran GG, Melek IM, Duman T, Gunesacar R.Investigation of the Relationship Between SerumSolubl Fas (sFas), Soluble Fas Ligand (sFasL) Levelsand FAS-FASLG Polymorphisms in Patients withMultiple Sclerosis. Dicle Med J 2020; 47: 331-9.

22.Horton M, Rudick RA, Hara-Cleaver C, Marrie RA.Validation of a Self-report comorbidityquestionnaire for multiple sclerosis.Neuroepidemiology 2010; 35: 83–90. doi:10.1159/000311013.

23.Levinthal DJ, Rahman A, Nusrat S, et al. Adding tothe burden: gastrointestinal symptoms andsyndromes in multiple sclerosis. Mult Scler Int 2013:319201. doi: 10.1155/2013/319201.

24.Marrie R, Horwitz R, Cutter G, et al. Comorbidity,socioeconomic status, and multiple sclerosis. MultScler 2008; 14: 1091–1098. doi:10.1177/1352458508092263.

25.Marrie RA, Yu BN, Leung S, et al.; CIHR Team inthe Epidemiology and Impact of Comomrbidity onMultiple Sclerosis. The utility of administrative datafor surveillance of comorbidity in multiple sclerosis:a validation study. Neuroepidemiology 2013; 40:85–92. doi: 10.1159/000343188.

26.Marrie RA, Horwitz RI, Cutter G, Tyry T, VollmerT.Association between comorbidity and clinicalcharacteristics of MS. Acta Neurol Scand2011;124:135–141. doi: 10.1111/j.1600-0404.2010.01436.x.